An Observation Study Concerning Efficacy of Meloxicam in the Prevention of Formation of Heterotopic Ossification Following THA

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-12002364

Enrollment

Unknown

Registered

2012-07-22

Start date

2010-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Formation of Heterotopic Ossification Following THA

Interventions

B (30 hips):Meloxicam 15mg/d for 6 weeks

A (28 hips):Indomethacin sustained released tablets 25mg/time and 2 times/d, and gastric mucosa protection drugs

Eligibility

Sex/Gender

All

Age

26 Years to 77 Years

Inclusion criteria

Inclusion criteria: patients who accepted THA, which age ranged from 20 to 80.

Exclusion criteria

Exclusion criteria: patients who had long-term NSAIDs usage history,malignant tumor,contradictions of non-selective NSAIDs because of relevant diseases(such as peptic ulcer,asthma and so on.), clear cardiovascular diseases(such as hypertension, coronary diseases and so on), and history of mental illness.

Design outcomes

Primary

Measure	Time frame
accidence of heterotopic ossification;	—

Secondary

Measure	Time frame
side effect;postoperative hip function;	—

Countries

China

Contacts

Public ContactZeng Yingrong

zengyirong@163.com+86 13711456292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026